ArticleBMC public health2026
Survival and mortality predictors among children living with HIV initiating antiretroviral therapy in Angola: a retrospective cohort study.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundChildren living with HIV continue to face high mortality rates in resource-limited settings, especially in sub-Saharan Africa. In Angola, there is a lack of robust data to guide clinical and programmatic strategies targeting this vulnerable population. This study aimed to estimate survival and identify predictors of mortality in children with HIV followed up at a paediatric referral hospital in Angola.
methodsA retrospective cohort study of children (≤ 15 years) who started ART between 2016 and 2018, with follow-up until 2023. Kaplan-Meier curves and Cox regression models were used to estimate survival and identify factors associated with death.
resultsDuring 1,577 person-years of follow-up, a total of 420 deaths occurred, corresponding to a mortality rate of 26.6 deaths per 100 person-years. The median follow-up time was 11.9 months (interquartile range: 3.4-38.5). Median survival was significantly lower among children with non-vertical transmission, WHO clinical stage III/IV, CD4 counts below the age-specific threshold, underweight status, and opportunistic infections. In the multivariable Cox model including transmission route, WHO clinical stage, baseline CD4 count, underweight status, and age group, non-vertical transmission (AHR 1.35, 95% CI 1.11-1.65), WHO clinical stage III/IV (AHR 1.82, 95% CI 1.36-2.46), and CD4 below the age-specific threshold (AHR 1.82, 95% CI 1.06-3.12) remained independent predictors of mortality.
conclusionThe high mortality observed in this cohort was associated with advanced clinical severity at admission. The finding that non-vertical transmission was independently associated with mortality suggests the need for improved screening and tailored care strategies for children and adolescents infected outside the mother-to-child context. Strengthening early diagnosis and timely initiation of ART is crucial to reducing preventable deaths and achieving global paediatric HIV control targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.